<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15802">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107952</url>
  </required_header>
  <id_info>
    <org_study_id>0015</org_study_id>
    <nct_id>NCT00107952</nct_id>
  </id_info>
  <brief_title>Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus</brief_title>
  <acronym>ATTAIN1</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma Antibiotics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Argentina: Human Research Bioethics Committee</authority>
    <authority>Argentina: Ministry of Health</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Belgium: Institutional Review Board</authority>
    <authority>Belgium: Ministry of Social Affairs, Public Health and the Environment</authority>
    <authority>Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment</authority>
    <authority>Brazil: Ethics Committee</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Canada: Canadian Institutes of Health Research</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Canada: Ministry of Health &amp; Long Term Care, Ontario</authority>
    <authority>Chile: Comisión Nacional de Investigación Científica y Tecnológica</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>Croatia: Agency for Medicinal Product and Medical Devices</authority>
    <authority>Croatia: Ethics Committee</authority>
    <authority>Croatia: Ministry of Health and Social Care</authority>
    <authority>Croatia: Ministry of Science, Education and Sports</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Direction Générale de la Santé</authority>
    <authority>France: French Data Protection Authority</authority>
    <authority>France: Haute Autorité de Santé Transparency Commission</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Ministry of Health</authority>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Greece: Ministry of Health and Welfare</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>India: Indian Council of Medical Research</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Israel: The Israel National Institute for Health Policy Research and Health Services Research</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Italy: National Bioethics Committee</authority>
    <authority>Italy: National Institute of Health</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>Malta: Medicines Authority</authority>
    <authority>Peru: Ethics Committee</authority>
    <authority>Peru: General Directorate of Pharmaceuticals, Devices, and Drugs</authority>
    <authority>Peru: Ministry of Health</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Poland: Ministry of Science and Higher Education</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>South Africa: Department of Health</authority>
    <authority>South Africa: Human Research Ethics Committee</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>South Africa: National Health Research Ethics Council</authority>
    <authority>Taiwan: Department of Health</authority>
    <authority>Taiwan: Institutional Review Board</authority>
    <authority>Taiwan: National Bureau of Controlled Drugs</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Department of Health</authority>
    <authority>United Kingdom: Food Standards Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: National Health Service</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug,
      telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>7 - 14 days following end of antibiotic treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Response: Categorical (Cured, Failed or Indeterminate)
Failure is at least one of the following: Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy; Termination of study med due to &quot;lack of efficacy&quot;; Death on or after Day 3 attributable to primary infection
Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress.
Indeterminate: Inability to determine outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">761</enrollment>
  <condition>Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Telavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telavancin</intervention_name>
    <description>Telavancin 10 mg/kg/day IV for up to 21 days.</description>
    <arm_group_label>Telavancin</arm_group_label>
    <other_name>TD-6424</other_name>
    <other_name>VIBATIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin 1 Gm IV q 12 hrs for up to 21 days</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs and symptoms consistent with pneumonia acquired after at least 48
             hours of continuous stay in an inpatient acute or chronic care facility or acquired
             within 7 days after being discharged from a hospitalization of greater than or equal
             to 3 days duration.

        Exclusion Criteria:

          -  Received more than 24 hours of potentially effective systemic (IV, IM or PO)
             antibiotic therapy for Gram-positive pneumonia immediately prior to randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. Ralph Corey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 13, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2005</firstreceived_date>
  <firstreceived_results_date>November 3, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Steven Barriere, Pharm.D., Vice President, Clinical and Medical Affairs</name_title>
    <organization>Theravance, Inc.</organization>
  </responsible_party>
  <keyword>Nosocomial pneumonia</keyword>
  <keyword>MRSA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Telavancin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment Period: 08Feb05 to 11Jul07</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Telavancin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs.</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV administered every 12 hrs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="381"/>
                <participants group_id="P2" count="380"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
                <participants group_id="P2" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never received study treatment</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telavancin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs.</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV administered every 12 hrs.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="372"/>
                <measurement group_id="B2" value="374"/>
                <measurement group_id="B3" value="746"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="170"/>
                <measurement group_id="B2" value="162"/>
                <measurement group_id="B3" value="332"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="202"/>
                <measurement group_id="B2" value="212"/>
                <measurement group_id="B3" value="414"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63" spread="19.2"/>
                <measurement group_id="B2" value="64" spread="17.3"/>
                <measurement group_id="B3" value="64" spread="18.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="137"/>
                <measurement group_id="B2" value="161"/>
                <measurement group_id="B3" value="298"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="235"/>
                <measurement group_id="B2" value="213"/>
                <measurement group_id="B3" value="448"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="78"/>
                <measurement group_id="B2" value="66"/>
                <measurement group_id="B3" value="144"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="294"/>
                <measurement group_id="B2" value="308"/>
                <measurement group_id="B3" value="602"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="91"/>
                <measurement group_id="B2" value="87"/>
                <measurement group_id="B3" value="178"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="267"/>
                <measurement group_id="B2" value="272"/>
                <measurement group_id="B3" value="539"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Argentina</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="48"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Belgium</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Brazil</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Chile</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Croatia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="59"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Czech Republic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Greece</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>India</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="85"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="49"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Malaysia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Malta</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Peru</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South Africa</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Taiwan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="63"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Turkey</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="117"/>
                <measurement group_id="B2" value="113"/>
                <measurement group_id="B3" value="230"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Diabetes Status</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Diabetic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="100"/>
                <measurement group_id="B3" value="200"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-Diabetic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="272"/>
                <measurement group_id="B2" value="274"/>
                <measurement group_id="B3" value="546"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>History of Pneumonia</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Prior history of pneumonia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="115"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No prior history of pneumonia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="310"/>
                <measurement group_id="B2" value="321"/>
                <measurement group_id="B3" value="631"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ventilator Status</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Ventilated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="170"/>
                <measurement group_id="B2" value="171"/>
                <measurement group_id="B3" value="341"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-ventilated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="202"/>
                <measurement group_id="B2" value="203"/>
                <measurement group_id="B3" value="405"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response</title>
        <description>Clinical Response: Categorical (Cured, Failed or Indeterminate)
Failure is at least one of the following: Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy; Termination of study med due to “lack of efficacy”; Death on or after Day 3 attributable to primary infection
Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress.
Indeterminate: Inability to determine outcome</description>
        <time_frame>7 - 14 days following end of antibiotic treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Telavancin</title>
            <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV administered every 12 hrs.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="372"/>
                  <measurement group_id="O2" value="374"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Response</title>
            <description>Clinical Response: Categorical (Cured, Failed or Indeterminate)
Failure is at least one of the following: Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy; Termination of study med due to “lack of efficacy”; Death on or after Day 3 attributable to primary infection
Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress.
Indeterminate: Inability to determine outcome</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Cured</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="214"/>
                  <measurement group_id="O2" value="221"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority margin of 20% was specified based on historical regulatory precedent.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
            <estimate_desc>Statistical analysis applies to &quot;cure&quot;</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Telavancin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs.</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV administered every 12 hrs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pituitary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Multi-organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Clostridium Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury asphyxiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Tracheal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic hyperosmolar non-ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Nervous System Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Obstructive Uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Airways Disease Exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Dependence on Respirator</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Shock Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="317" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anasarca</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Infusion site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Multi-organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT Corrected interval prolonged</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Overland</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitis Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steve Barriere, Pharm.D., Vice President, Clinical and Medical Affairs</name_or_title>
      <organization>Theravance Biopharma Antibiotics, Inc.</organization>
      <phone>650-808-6132</phone>
      <email>sbarriere@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
